Caraco announces reduction of its Board of Directors.DETROIT, Mich.--(HealthWire)--Sept. 19, 1996--Caraco Pharmaceutical Laboratories, Ltd. (BULLETIN BOARD: CARA CARA Chicago Area Runners Association CARA Center for Applied Research in the Apostolate (Washington, DC) CARA Center for Astrophysical Research in Antarctica CARA Classification and Rating Administration ) today announced that it has reduced its Board of Directors from 11 to 7 members. In doing so Caraco accepted resignations from Betty R. Anderson, Ronald R. Dobbins, William R. Hurd, Theodore H. Glenn, and Robert P. Roselle Roselle (rōzĕl`), borough (1990 pop. 20,314), Union co., NE N.J.; set off from Linden 1890 and inc. 1894. Chiefly residential, the borough has some industry. . Present directors include David W. Adamany, C. Arnold Curry, Cara J. Curry, David A. Hagelstein, Jay F. Joliat and John R. Morris. Dr. Phyllis Harrison-Ross was elected to Caraco's Board as its seventh member. Dr. Harrison-Ross has more than 25 years in the community mental health profession. She presents a remarkably diverse career as a hospital administrator, researcher, academician, public health consultant, forensic psychiatrist and public educator. Dr. Harrison-Ross trained as an adult and child psychiatrist child psychiatrist Psychiatry A psychiatrist specialized in mental, emotional, or behavior disorders of children and adolescents; CPs are qualified to prescribe medications as well as a pediatrician, and continues to lend her administrative and clinical talents to serving the diverse, hard-to-reach and underserved population of New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . Caraco's Board stated that Dr. Harrison-Ross is a welcome addition to the Board. Her broad background will bring valuable perspective and insights to the company and will help fashion the future plans of Caraco. Caraco Pharmaceutical Laboratories, Ltd. is engaged in developing, manufacturing and marketing generic drugs for the ethical and over-the-counter markets. In August 1995, the company signed a distribution agreement with leading pharmaceutical and health care product distributor McKesson Drug Company, a subsidiary of $13 billion McKesson Corp. (NYSE NYSE See: New York Stock Exchange :MCK MCK McKinsey & Company (consulting firm) MCK Mohawk Council of Kahnawake (Quebec) MCK Mon Colle Knights (children's TV show) MCK Mirror Classes Kit MCK Maintenance Check ), which provides Caraco with access to McKesson's existing distribution networks. Among Caraco's 14 generic products, are Nifedipine nifedipine /ni·fed·i·pine/ (ni-fed´i-pen) a calcium channel blocking agent used as a coronary vasodilator in the treatment of coronary insufficiency and angina pectoris; also used in the treatment of hypertension. , a calcium blocker for the cardiovascular market, SureLac(TM), a lactase enzyme tablet which permits enjoyment of dairy products without discomfort, and additional products used for pain relief, sleeplessness, and coughs and colds. CONTACT: Caraco Pharmaceutical Laboratories, Ltd., Detroit William R. Hurd, 313/871-8400 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion